Skip to main content
    R

    Regeneron Pharmaceuticals Inc (REGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $952.40
    -3.07 (-0.32%)

    Market Cap: $98.84B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Regeneron Pharmaceuticals Inc (REGN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Regeneron Pharmaceuticals are BeOne Medicines AG (ONC), Moderna (MRNA) and argenx NV ADR (ARGX). Regeneron Pharmaceuticals trades at 18.4x earnings, against a median of 33.5x for the 5 of these companies with a P/E. By market cap, Regeneron Pharmaceuticals ranks 2nd of the 13 companies on this page; Vertex Pharmaceuticals (VRTX) is the largest at $136.56B.

    Peer Comparison

    REGN's ROIC of 13.7% is above the peer median of -28.5%, and its revenue growth of 36.3% is above the median of 22.6%. It yields 0.39%, while the median peer pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Regeneron Pharmaceuticals (REGN)$98.84B18.4x5.7x28.5%13.7%36.3%0.39%
    BeOne Medicines AG (ONC)$47.58B50.0x18.7x13.9%7.5%33.8%0.00%
    Moderna Inc (MRNA)$90.38BN/A34.2x-110.5%-28.9%29.2%0.00%
    argenx NV ADR (ARGX)$60.37B33.5x6.1x31.7%N/A52.1%0.00%
    Vertex Pharmaceuticals Inc (VRTX)$136.56B30.0x10.5x30.7%14.2%11.8%0.00%
    Royalty Pharma Plc (RPRX)$39.85B12.9x11.7x25.7%7.6%13.3%1.37%
    Genmab AS (GMAB)$31.67B35.8x19.2x17.0%4.8%16.1%0.00%
    Revolution Medicines Inc (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Insmed Inc (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Peer median$34.47B33.5x17.7x0.0%-28.5%22.6%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Regeneron Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    BeOne Medicines AG (ONC)
    BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe...
    ONC competitors
    Moderna Inc (MRNA)
    Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology...
    MRNA competitors
    argenx NV ADR (ARGX)
    argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases...
    ARGX competitors
    Vertex Pharmaceuticals Inc (VRTX)
    Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
    VRTX competitors
    Royalty Pharma Plc (RPRX)
    Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States.
    RPRX competitors
    Genmab AS (GMAB)
    Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
    GMAB competitors
    Revolution Medicines Inc (RVMD)
    Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted...
    RVMD competitors
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Insmed Inc (INSM)
    Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases.
    INSM competitors

    Frequently Asked Questions About REGN

    Who are Regeneron Pharmaceuticals' main competitors?

    The companies most similar to Regeneron Pharmaceuticals include BeOne Medicines AG (ONC), Moderna (MRNA), argenx NV ADR (ARGX), Vertex Pharmaceuticals (VRTX) and Royalty Pharma Plc (RPRX), listed from the closest match.

    Who is Regeneron Pharmaceuticals' biggest competitor?

    Vertex Pharmaceuticals (VRTX) is the largest of the similar companies at $136.56B; BeOne Medicines AG (ONC) is the closest match by business profile, size, sector and industry.

    How does REGN stock compare with its competitors?

    REGN's P/E is 18.4x against a peer median of 33.5x; its P/S is 5.7x against a peer median of 17.7x; its net margin is 28.5% against a peer median of 0.0%.

    Which of Regeneron Pharmaceuticals' competitors pays a higher dividend?

    Regeneron Pharmaceuticals has a forward dividend yield of 0.39%. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.

    Is Regeneron Pharmaceuticals bigger than its competitors?

    No. Regeneron Pharmaceuticals is 2nd by market cap among the 13 companies on this page; the largest is Vertex Pharmaceuticals (VRTX) at $136.56B.